Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…
McAlinden Research PartnersApril 18, 2023
AI is transforming industries across every sector of the economy. Biotech and pharma are now experiencing a boom in AI initiatives…
McAlinden Research PartnersJuly 27, 2021
As the massive 2700-case litigation against major producers and distributors of opioids continues in Ohio, many lawyers and Attorneys General…
McAlinden Research PartnersOctober 23, 2019
In two back-to-back blockbuster headlines, Johnson & Johnson was found liable for damages related to the US opioid crisis and…
McAlinden Research PartnersAugust 28, 2019
As litigation against some of the world’s foremost drugmakers finally enters the courtroom, some companies have already settled a number…
McAlinden Research PartnersJune 25, 2019
At first glance, first quarter earnings for the pharmaceutical sector appear to be largely positive, with only a few nuggets…
McAlinden Research PartnersMay 1, 2019
Investors seeking a more defensive positioning have rushed into health care stocks in recent months, as hype about the aging…
McAlinden Research PartnersFebruary 4, 2019
The Trump Administration may finally be taking serious action against the pharmaceutical industry in a bid to cut down heavily…
McAlinden Research PartnersOctober 30, 2018
The administration has, thus far, taken measured action against drug prices since President Trump announced his “blueprint” to tackle high…
McAlinden Research PartnersAugust 15, 2018
